FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

What this study is about

This study will include patients with invasive cervical cancer that wish to keep their fertility as much as possible in the future after treatment. Patients who receive surgery alone may experience long-term side effects including infertility. The purpose of this research study is to determine whether giving neo-adjuvant chemotherapy prior to surgery can maintain fertility in patients with invasive cervical cancer. The neo-adjuvant chemotherapy will consist of a platinum-based chemotherapy drug cisplatin or carboplatin, with a chemotherapy drug called paclitaxel. These are common chemotherapy drugs used in the treatment of women with cervical cancers.

Who can join (things the study team will check)

✅ You may be able to join if…

• Patients must have histologically confirmed invasive cervical cancer with adenocarcinoma, adenosquamous or squamous histology and FIGO 2018 IB2 measuring >2 cm - ≤4 cm by radiological imaging (MRI).
• Patients must be premenopausal and wish to preserve fertility.
• At time of registration, patient may not have had any prior therapy to treat their cancer lesion.
• Eastern Cooperative Group (ECOG) performance status ≤ 2.
• Within 7 days of the proposed start of treatment, patients must have normal organ and marrow function.
• No evidence of active uncontrolled infection (patients on antibiotics are eligible).
• Patient must have disease that is measurable per the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
• Ability to understand and willing to sign a written informed consent document.
• Patients must agree to use effective contraceptive methods prior to study entry, during study participation, and for at least one year after the fertility-sparing surgery (FSS) procedure. A serum pregnancy test within 72 hours prior to study registration is required. Part 2 - Eligibility Criteria for Fertility Sparing Surgery (FSS)
• Completed 3 cycles of neo-adjuvant chemotherapy and achieved a complete response (CR) or partial response (PR) with reduction of the lesion to <2 cm on physical examination and MRI.

🚫 You may not be able to join if…

• Patients who have had chemotherapy or radiotherapy or surgery for their cancer.
• Patients who are receiving any other investigational agents.
• Patients with other cancers requiring ongoing treatment.
• Patients with known / evidence of brain metastases are excluded from participation in this clinical trial.
• History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel, carboplatin, or cisplatin or other agents used in study.
• Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• Patients who are pregnant or breastfeeding
• Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues. Part 2 - Exclusion Criteria for Fertility Sparing Surgery
• Patient unable to complete 3 cycles of neoadjuvant chemotherapy
• Suboptimal response to neoadjuvant chemotherapy according to investigator
• Residual lesion > 2cm or disease progression while on chemotherapy

Where this trial is running

• MD Anderson Cancer Centre, Houston, Texas, United States
• Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
• Princess Margaret Cancer Centre, Toronto, Ontario, Canada
• L'Hôtel-Dieu de Québec, Québec, Quebec, Canada

Who to contact

Stephanie Lheureux, M.D. · 416-946-2818 · stephanie.lheureux@uhn.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04016389.